Vahakn B Shahinian

Summary

Affiliation: University of Texas Medical Branch
Country: USA

Publications

  1. pmc Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist
    Vahakn B Shahinian
    Department of Internal Medicine, University of Texas Medical Branch, John Sealy Annex 4 200, 301 University Blvd, Galveston, TX 77555 0562, USA
    J Natl Cancer Inst 98:839-45. 2006
  2. ncbi request reprint Risk of fracture after androgen deprivation for prostate cancer
    Vahakn B Shahinian
    Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 0562, USA
    N Engl J Med 352:154-64. 2005
  3. ncbi request reprint Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma
    Vahakn B Shahinian
    Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555 0562, USA
    Cancer 103:1615-24. 2005
  4. pmc Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer
    Vahakn B Shahinian
    Department of Internal Medicine, and Sealy Center on Aging, University of Texas Medical Branch, Galveston, TX 77555 0562, USA
    Arch Intern Med 166:465-71. 2006
  5. pmc Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer
    Vahakn B Shahinian
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0725, USA
    J Clin Oncol 25:5359-65. 2007
  6. doi request reprint Reimbursement policy and androgen-deprivation therapy for prostate cancer
    Vahakn B Shahinian
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0725, USA
    N Engl J Med 363:1822-32. 2010
  7. pmc Reducing bias in the assessment of treatment effectiveness: androgen deprivation therapy for prostate cancer
    Yong Fang Kuo
    Department of Internal Medicine, Sealy Center on Aging, University of Texas Medical Branch, Galveston, TX 77555 0177, USA
    Med Care 50:374-80. 2012
  8. pmc Cause of death in older men after the diagnosis of prostate cancer
    Melanie Ketchandji
    University of Texas Medical Branch, Galveston, Texas, USA
    J Am Geriatr Soc 57:24-30. 2009
  9. pmc Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer
    Yong Fang Kuo
    Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA
    BMC Health Serv Res 8:146. 2008
  10. pmc Comparison of stage at diagnosis of cancer in patients who are on dialysis versus the general population
    Shilpa Taneja
    Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
    Clin J Am Soc Nephrol 2:1008-13. 2007

Detail Information

Publications14

  1. pmc Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist
    Vahakn B Shahinian
    Department of Internal Medicine, University of Texas Medical Branch, John Sealy Annex 4 200, 301 University Blvd, Galveston, TX 77555 0562, USA
    J Natl Cancer Inst 98:839-45. 2006
    ....
  2. ncbi request reprint Risk of fracture after androgen deprivation for prostate cancer
    Vahakn B Shahinian
    Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX 77555 0562, USA
    N Engl J Med 352:154-64. 2005
    ..This treatment is associated with a loss of bone-mineral density, but the risk of fracture after androgen-deprivation therapy has not been well studied...
  3. ncbi request reprint Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma
    Vahakn B Shahinian
    Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555 0562, USA
    Cancer 103:1615-24. 2005
    ..The authors examined the time trends and patterns of use for androgen deprivation in the form of gonadotropin-releasing hormone (GnRH) agonists or orchiectomy, in population-based tumor registries...
  4. pmc Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer
    Vahakn B Shahinian
    Department of Internal Medicine, and Sealy Center on Aging, University of Texas Medical Branch, Galveston, TX 77555 0562, USA
    Arch Intern Med 166:465-71. 2006
    ..We therefore sought to estimate the incidence of these effects and, by using a control group, ascertain whether these effects were related to androgen deprivation itself...
  5. pmc Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer
    Vahakn B Shahinian
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0725, USA
    J Clin Oncol 25:5359-65. 2007
    ..Using the Surveillance, Epidemiology, and End Results-Medicare linked database, we examined how individual urologist characteristics influenced the use of androgen deprivation therapy...
  6. doi request reprint Reimbursement policy and androgen-deprivation therapy for prostate cancer
    Vahakn B Shahinian
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0725, USA
    N Engl J Med 363:1822-32. 2010
    ..We hypothesized that these reductions would lead to decreases in the use of ADT for indications that were not evidence based...
  7. pmc Reducing bias in the assessment of treatment effectiveness: androgen deprivation therapy for prostate cancer
    Yong Fang Kuo
    Department of Internal Medicine, Sealy Center on Aging, University of Texas Medical Branch, Galveston, TX 77555 0177, USA
    Med Care 50:374-80. 2012
    ..We explored the potential advantages of using an instrumental variable approach in the context of primary androgen deprivation therapy (ADT) for prostate cancer...
  8. pmc Cause of death in older men after the diagnosis of prostate cancer
    Melanie Ketchandji
    University of Texas Medical Branch, Galveston, Texas, USA
    J Am Geriatr Soc 57:24-30. 2009
    ..To compare survival and cause of death in men aged 65 and older diagnosed with prostate cancer and with survival and cause of death in a noncancer control population...
  9. pmc Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer
    Yong Fang Kuo
    Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA
    BMC Health Serv Res 8:146. 2008
    ..We hypothesized that some men receive these agents after only a limited work-up for their cancer. Such cases may be missed by tumor registries, leading to underestimates of the total extent of GnRH agonist use...
  10. pmc Comparison of stage at diagnosis of cancer in patients who are on dialysis versus the general population
    Shilpa Taneja
    Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
    Clin J Am Soc Nephrol 2:1008-13. 2007
    ..It is therefore unclear whether dialysis patients are disadvantaged in terms of cancer diagnosis. This study compared stage at diagnosis of cancer in a population-based sample of patients with ESRD versus the general population...
  11. doi request reprint Estimating prevalence of CKD stages 3-5 using health system data
    Vahakn B Shahinian
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 2029, USA
    Am J Kidney Dis 61:930-8. 2013
    ..The feasibility of using health system data to estimate prevalence of chronic kidney disease (CKD) stages 3-5 was explored...
  12. ncbi request reprint Risk of malignancy with long-term immunosuppression in renal transplant recipients
    Mahendra L Agraharkar
    Division of Nephrology, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA
    Kidney Int 66:383-9. 2004
    ..Available data pertaining to cancer risks in renal transplant recipients have been inconsistent, and much of it is derived from international studies, which may not be truly representative of the United States population...
  13. ncbi request reprint Are chronic dialysis patients at increased risk for cancer?
    Sreedhar Mandayam
    Wichita Nephrology Group, Wichita, KS, USA
    J Nephrol 21:166-74. 2008
    ..Further research is needed before routine screening for bladder or renal cell cancers can be recommended...
  14. ncbi request reprint Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoroliferative disorder in adult renal allograft recipients
    Vahakn B Shahinian
    Multi Organ Transplant Unit, London Health Sciences Center, University of Western Ontario, London, Ontario, Canada
    Transplantation 75:851-6. 2003
    ..We investigated risk factors for PTLD in the adult renal transplant setting...